Monopar Therapeutics stock forecast: Downside risk remains high with sellers in control
Monopar Therapeutics (MNPR) stock is trading at $72.38, down 6.06% on the day. The price currently sits below its key moving averages, reflecting continued pressure from selling activity.
71.0100
79.4350
Highlights
- MNPR/USD stock trades below key short-, medium-, and long-term moving averages, confirming sustained downward pressure and weak price structure.
- Momentum indicators align in a strongly bearish stance, with multiple signals indicating deeply oversold conditions and persistent seller control.
- Given recent losses and alignment of bearish technicals, the forecasted range is $67.7116 to $77.0484, with a very high probability of further downside.
Bearish momentum persists as key technical signals stay negative
On the technical side, MNPR is currently trading below the MA-20, MA-50, and MA-200 levels on the working timeframe, highlighting weak structure and persistent downside momentum. The Ichimoku Kijun sits at $80.3156 and acts as immediate resistance. Both MACD and ADX register a Sell signal, with RSI at 30.86, Stoch RSI, CCI, and Bull/Bear Power all indicating deeply oversold conditions and clear seller dominance. The Awesome Oscillator is neutral, and no meaningful divergences are noted among the oscillators, as price action and indicator signals are aligned in a bearish direction.
Downside risk elevated as recovery hinges on resistance reclaim
Over the next few sessions, MNPR is expected to consolidate within the $67.7116–$77.0484 range. The probability of a move higher remains very low, while downside risk is assessed as very high. A bullish scenario would require the price to reclaim and hold above the $80.3156 resistance, while a break below $67.7116 support could accelerate losses further.
Earlier, analysts noted that Monopar Therapeutics shares were consolidating after a period of heightened volatility, with downside risk as the primary concern. The current technical landscape affirms this bearish outlook, underscoring the importance of monitoring $67.7116 as a critical support level for any further deterioration in price.
Latest Monopar Therapeutics News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
